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Abstract: Background: Hereditary ataxias are a heterogeneous group of degenerative diseases of the
cerebellum, brainstem, and spinal cord. They may present with isolated ataxia or with additional symptoms
going beyond cerebellar deficits. There are an increasing number of clinical studies with the goal to define
the natural history of these disorders, develop biomarkers, and investigate therapeutic interventions.
Especially, early and preclinical disease stages are currently of particular interest.
Methods and Results: Evidence-based, we review standards for sampling and storage of biomaterials, clinical
and neuropsychological assessment, as well as neurophysiology and neuroimaging and recommendations for
standardized assessment of ataxia patients in multicenter studies.
Conclusions: DNA, RNA, serum, and, if possible, cerebrospinal fluid samples should be processed following
established standards. Clinical assessment in ataxia studies must include use of a validated clinical ataxia
scale. There are several validated clinical ataxia scales available. There are no instruments that were
specifically designed for assessing neuropsychological and psychiatric symptoms in ataxia disorders. We
provide a list of tests that may prove valuable. Quantitative performance tests have the potential to
supplement clinical scales. They provide additional objective and quantitative information. Posturography and
quantitative movement analysis—despite valid approaches—require standardization before implemented in
multicenter studies. Standardization of neurophysiological tools, as required for multicenter interventional
trials, is still lacking. Future multicenter neuroimaging studies in ataxias should implement quality assurance
measures as defined by the ADNI or other consortia. MRI protocols should allow morphometric analyses.
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Hereditary ataxias are a clinically and genetically heteroge-
neous group of degenerative diseases of the cerebellum,
brainstem, and spinal cord. Their prominent clinical features
are progressive ataxia comprising impairment of gait, balance,
and limb coordination, as well as disturbances of speech swal-
lowing and oculomotor control. Hereditary ataxias may
present as purer forms with more isolated ataxia or as com-
plicated forms with additional neurological symptoms.
Hereditary ataxias are subdivided into the autosomal-recessive
ataxias with Friedreich’s ataxia (FRDA) as the most prevalent
entity -except East Asia-, the autosomal-dominant ataxias desig-
nated as spinocerebellar ataxias (SCAs), and X-linked ataxias
with fragile X-associated tremor ataxia syndrome (FXTAS) as
the most common form. Currently, more than 50 recessive
ataxias (http://neuromuscular.wustl.edu/ataxia/recatax.html),
and approximately 40 SCAs, have been genetically delineated
(http://neuromuscular.wustl.edu/ataxia/domatax.html). Addi-
tionally, ataxias can be caused by mitochondrial DNA mutations
as well. A subgroup of potentially hereditary ataxias are the
sporadic adult-onset degenerative disorders with no identified
etiology share many clinical features with the hereditary ataxias,
but the causes of these ataxias are unknown. An overview of
hereditary ataxias and causative gene mutations can be found
online (http://neuromuscular.wustl.edu/).
With the genetic classification of hereditary ataxias, an
increasing number of clinical studies aim to define the natural
history of these disorders, develop biomarkers, and investigate
therapeutic interventions. Early and preclinical disease stages are
currently attracting particular interest. For such studies, generally
accepted standards for sampling and storage of biomaterials, clin-
ical and neuropsychological assessment, quantitative performance
tests, as well as neuroimaging are highly needed. In this article,
we review the available evidence and give recommendations for
standardized assessment of ataxia patients in multicenter studies.
Methods
Searches were conducted in the MEDLINE, EFNS Guidelines,
and EMQN databases. The review period was from January
1990 to 2014. Original articles, review articles, and guideline
recommendations were reviewed. Search terms were hereditary
ataxia, cerebellar ataxia, autosomal-recessive ataxia, Friedreich’s
ataxia, spinocerebellar ataxia, autosomal-dominant cerebellar
ataxia, and Machado-Joseph disease and were used in various
combinations with terms like clinical assessment scales, func-
tional score, MRI, PET, gait analysis, genotyping, biomarker,
biomaterial, morpho*, and neuropsycho*. In the next step, the
identified assessments tools, such as “Scale for the Assessment
and rating of Ataxia” (“SARA”), “International Cooperative
Ataxia Rating Scale” (“ICARS”), “Composite Cerebellar Func-
tional Severity Score” (“CCFS”), were used as search terms in
combination with disease terms. Reference lists of publications
of interest were screened for other relevant studies. B.P. per-
formed the literature search and wrote the first draft. T.K.
reviewed all versions. A preliminary version of the manuscript
was then circulated among all authors. This version was dis-
cussed and consented by conference calls, before the final ver-
sion was drafted and circulated.
Ataxia Research Consortia and
Study Groups
In recent years, a number of large national and international
research consortia have received public funding to perform clin-
ical research in hereditary ataxias. SPATAX is a consortium of
European and North African investigators under French leader-
ship that focuses on clinical and genetic studies in recessive
ataxias and hereditary spastic paraplegias (HSPs) (http://spatax.
wordpress.com/). The EUROSCA Clinical Network that was
funded by the European Union (EU) between 2004 and 2008
developed clinical assessment tools for ataxia, established an
electronic database, and initiated a natural history study of dom-
inantly inherited spinocerebellar ataxias (SCAs) (http://
www.eurosca.org). To continue clinical research activities,
investigators of the EUROSCA Clinical Network in 2008
founded the Ataxia Study Group (ASG) (http://www.
ataxia-study-group.net/html/about). Currently, there are two
large EU-funded consortia involved in clinical ataxia and HSP
research. Major initiatives to study FRDA are performed by
EFACTS (http://www.e-facts.eu) in Europe and the Coopera-
tive Clinical Research Network (CCRN) in the United States,
Canada, Brazil, and Australia. NeurOmics is using -omics meth-
ods to find disease causing genes, improve diagnostics, and
develop novel therapies for 10 rare neurodegenerative and
neuromuscular disease groups, including ataxia (http://rd-
neuromics.eu/). The Cerebellar Ataxia Group (CAG), which
has evolved into the Clinical Research Consortium for Studies
of Cerebellar Ataxias (CRC-SCA), comprises North American
ataxia investigators. Clinical studies initiated by the CRC-SCA
received funding from the National Institutes of Health
(NIH). The Japanese Ataxia Study Group receives funding
from the Japanese government. It is running a large patient
registry.
Common Data Elements
Starting in 2006, the National Institute of Neurological Disor-
ders and Stroke (NINDS) and other federal agencies and inter-
national organizations have the common mission of developing
data standards for clinical research. On their webpage (http://
www.commondataelements.ninds.nih.gov/ProjReview.aspx#tab
=Introduction), common as well as disease-specific data ele-
ments are published as a resource to build study specific com-
mon data element (CDE) data collection sheets. General CDEs
include medical history data; scores on neurological assessments;
demographic information (e.g., date of birth/age, race, and eth-
nicity); and details about medications used by participants
throughout a study. For FRDA, disease-specific recommenda-
tions of tools and CDEs are given by NINDS (http://www.
commondataelements.ninds.nih.gov/Doc/
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FA/FA_CDE_Highlight_Summary.pdf).1 CDEs for other forms
of ataxias are not available yet.
Biomaterial Sampling and
Storage
Availability of biomaterials is an essential prerequisite for
progress in the understanding of neurodegenerative diseases.
Genetic testing is performed for genetic classification of study
participants. On http://www.scabase.eu, information about
ataxia genetics regarding current best practices protocols for
molecular genetic testing, lists of repeat sequences, primers, and
normal and pathogenic repeat sizes on the main loci are main-
tained.
Orphanet and—in Europe—EuroGenTest are data sources
for genetic tests and relevant laboratories.
DNA is needed for the proper classification of study subjects
with known diseases and for identification of novel disease
genes and genetic modifiers.
Fibroblast or peripheral blood mononuclear cell (PBMC)
samples are valuable sources for various experiments, in particu-
lar, generation of induced pluripotent stem cells (iPSC). Because
sampling of PBMCs is less invasive and easier than that of
fibroblasts, PBMCs are the currently recommended source of
iPSCs.2 Given the enormous potential of research with iPSCs,
routine sampling of PBMCs in clinical studies, if feasible, is
highly recommended.3
There are several systematic efforts for brain collections under
standardized protocol. Here as well, effort and money are limit-
ing factors. Additionally, the trust of potential donors and their
families plays an important role in the success of building up
brain collections.
Biomaterials, such as blood samples, urine, and cerebrospinal
fluid (CSF), are required for the development of fluid biomark-
ers, which—other than in common neurodegenerative diseases,
such as Alzheimer’s disease (AD)—are currently not available in
ataxia.
Usefulness of biomaterials critically depends on the clinical
information on the subjects from whom the materials are
derived. Biomaterial collections that are not linked to reliable
clinical data are therefore of limited use. Another important
aspect that is critical for the usefulness of biomaterials is the bio-
physical quality of the samples.4 All procedures, including
acquisition, handling, and preprocessing before final storage,
storage, and retrieval, strongly influence the composition and
stability of the samples. These steps should be therefore per-
formed following standard operation procedures, as are generally
recommended for biomaterial banking.3,5,6 Furthermore, a doc-
umentation of the biomaterial quality is necessary and should
be performed as detailed and internationally comprehensive as
possible. An example of such documentation is the standard
preanalytical (SPREC) code (http://www.isber.org/?page=
SPREC).7 For further information see supplemental material.
Overall, DNA, RNA, serum, and—whenever possible—CSF
and PBMC samples comprise a set of biomaterials that should
be taken.
Clinical Scales
Clinical scales are the most important component of assessment
in clinical studies. They serve as outcome measures in clinical
interventional trials and are therefore key instruments that have a
strong impact on future research and patient care. Clinical ataxia
scales have been recently reviewed in detail.8 We will describe
here the most widely used scales and comment on their proper-
ties with respect to use in multicenter and longitudinal studies.
Their basic psychometric properties are summarized in Table 1.
ICARS9
The ICARS was the first ataxia scale and is widely used in
observational studies as well as in interventional trials. It consists
of 19 items grouped into four subscales that contribute to a total
score of 100 points. Subdivisions of different ataxia components
are postural and gait disturbance, limb ataxia, dysarthria, and
oculomotor disorders.9
ICARS has been evaluated in six published studies in MSA,
SCA, and FRDA patients.10 Standard psychometric variables,
such as total Crohnbach’s a, inter-rater reliability, and test-retest
reliability, were reported to be good to very good. However,
several investigators observed interdependencies between several
items. Furthermore, principal component analysis showed that
the ICARS score is determined by four different factors that do
not coincide with the subscales. The ICARS also lacked linear-
ity and showed floor and ceiling effects.11 However, ICARS
shows good sensitivity to change.
There are two modified versions of the ICARS, the Brief
Ataxia Rating Scale (BARS) for use by movement disorder
specialists and general neurologists, and the modified ICARS
(MICARS), in which further items were added.12 Both
scales lack further validation. Recently, the effect of age on
ICARS, BARS, and SARA scores has been assessed in healthy
children.
SARA13
The SARA is a clinical scale based on a semiquantitative
assessment of cerebellar ataxia. It has eight unequally
weighted items evaluating to gait, stance, sitting, speech, fin-
ger-chase test, nose-finger test, fast alternating movements,
and heel-shin test. Oculomotor functions are not included in
the SARA.
The SARA was initially validated in two studies of 167 and
119 SCA patients.13,14 Subsequent evaluation studies were done
in mixed populations of ataxia patients15 and in FRDA.16 The
SARA has been translated into Iberia-Brazilian, Japanese, and
Chinese versions, and the translated versions were also validated.
Recently, the SARA was also tested in healthy children of vari-
ous age groups.10
Overall, psychometric properties were shown to be as good
as for the ICARS. In contrast to the ICARS, the SARA
behaves linearly without ceiling or floor effects. In FRDA
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patients, sensitivity to change of SARA was greater than that of
the Friedreich Ataxia Rating Scale (FARS) and ICARS.17 In
addition, clinically relevant changes were defined, and it was
demonstrated that SARA is a major determinant of health-
related quality of life in SCA patients. From the practical point
of view, SARA has less repetitive items, is less time-consuming
to administer, and easier to use than ICARS.
FARS18
The FARS comprises neurological signs that specifically
reflect FRDA symptoms assessed in three functional domains:
(1) functional staging (overall mobility); (2) activity of daily
living (ADL); (3) neurological assessments (bulbar, upper and
lower limbs, peripheral nerve, upright stability, and gait func-
tions). The FARS has been validated in two studies of 14
and 155 FRDA patients, respectively.18 Regner et al. dis-
cussed that for longitudinal measurement in unselected
cohorts, a 2-year period may be the minimum period to gain
reasonable power.19
Psychometric properties were good and comparable to
ICARS and SARA. However, ceiling effects were observed.
FARS meets essential criteria for validity for the measurement
of disease progression. As a measure of sensitivity, FARS has
greater effect size in FARDA patients than ICARS.16,17
Neurological Examination Score for
Spinocerebellar Ataxia20
The Neurological Examination Score for Spinocerebellar Ataxia
(NESSCA) was developed specifically for SCA3 patients based
on a standardized neurological examination. Thus, the 18 items
selected comprise a global inventory of general neurological
signs and of signs specific for SCA3. It has been validated in a
cross-sectional study of 99 SCA3 patients. Inter-rater reliability
(20 patients) was high. Scores correlated with SARA scores.
Sensitivity to change was not investigated.
Scales for the Assessment and
Rating of Nonataxia Features
Inventory of Non Ataxia Signs21
The Inventory of Non Ataxia Signs (INAS) comprises a list of
various nonataxia signs that often occur in ataxia patients and of
cerebellar oculomotor signs that are not considered in the
SARA. INAS has 30 items related to neurological signs, such as
spasticity, and to reported abnormalities, such as dysphagia. The
items are grouped into functional categories, reflecting 16 nona-
taxia and cerebellar oculomotor signs.21 As a simple quantitative
measure, the INAS count reflects the presence or absence of
TABLE 1 Psychometric features of ataxia rating scales and functional performance scores
Name Internal
Consistency
(Crohnbach’s a)
Inter-rater
Reliability
(ICC)
Test-Retest
Reliability
(ICC)
Sensitivity to Change Scale References
Generic ataxia scales
ICARS 0.94 (FRDA),
0.95 (SCA)
0.95 0.93 (FRDA),
0.97 (SCA)
ES: 0.26 0–100 points 8,10–12
SARA 0.94 0.98 0.90 ES: =<0.2; SRM: 0.5 0–40 points 13,14
Disease-specific ataxia scales
FARS 0.86 0.95 0.95 Part I–III: ES: 0.34 ES:
0.34; SRM: 0.53
Part I: 0–6 points;
Part II: 0–36 points;
Part III:
0–117 points
15
NESSCA 0.77 0.97 n/a ES: 0.22 0–40 16
Nonataxia symptoms inventory
INAS n/a 0.88 0.65 SRM: 0.26 0–16 points 17
Functional performance tests
ACFS n/a 0.92 (PATA),
0.93 (9HPT,
T25FW)
n/a SRM: 9HPT: 0.43, T25FW:
0.26; LCLA: 0.19; PATA:
no change; z2 score: 0.37;
z3 score: 0.39; ES: 0.34;
SRM: 0.53
Continuous; arithmetic
mean across
all three z scores
15,18
SCAFI 0.72 n/a n/a SRM: 0.48 Continuous; arithmetic
mean across
all three z scores
19
CCFS n/a n/a 0.92 [0.84,
0.97]
CCFS ES: <0.2,
SRM: 0.32CCFSw:
ES: <0,2, SRM:.0 40
Continuous; log10 z score,
electronic, validated
in children
20,21
ICC, intraclass correlation; ES, effect size; SRM, standard response mean; n/a, not available; T25FW, timed 25 feet walk; LCVA, low-contrast
visual acuity.
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nonataxia signs, when at least one item related to a nonataxia
sign is present.
The INAS performed very well in terms of inter-rater and
test-retest reliability. There were mild floor and no ceiling effects.
Responsiveness and sensitivity, however, were less satisfactory.
Another limitation is that the INAS lacks precise definitions and
instructions for investigators, which may cause variability in judg-
ments of symptom severity. However, the INAS is an inventory
—not a rating—scale, so the score depends on the presence, not
on the severity of symptoms and signs. The INAS is easy to use,
only requiring tests or procedures that are routinely performed in
the neurological examination. Overall, it has proved to be a use-
ful supplement to the SARA, but it is not an appropriate primary
outcome measure in interventional trials in ataxia.
Other Scales
In some types of ataxias, specific symptoms are frequently
encountered. Examples are spasticity in autosomal recessive
spastic ataxia of Charlevoix-Saguenay (ARSACS) and auto-
nomic dysfunction in SCA3. In these instances, it is useful to
apply other scales that assess specific symptoms more accurately
than the INAS. In SCA3 patients, the Unified Multiple System
Atrophy Rating Scale (UMSARS) has been validated.22 In
ARSACS and other spastic ataxias, the Spastic Paraplegia Rating
Scale (SPRS), which has been developed for hereditary spastic
paraplegia patients,23 can be applied. However, further valida-
tion is desirable.
Patient-Reported Measures
Outcome measures that are patient reported may be valuable
for complementing physician-based outcomes. Examples for
generic health status measurement tools or disease-specific tools
are Short Form Health Survey version 2 (SF-36 V2)24 or the
Friedreich Ataxia Impact Scale (FAIS).25 The SF-36 is a general
measurement of quality of life. Quality of life is an important
secondary endpoint in clinical interventional trials. The SF-36
does not address many ataxia-related issues, though. The FAIS
contains 126 items covering eight functional areas. It was devel-
oped and validated in over 400 FRDA patients grouped into
different levels of disease severity. In a recent longitudinal study,
the FAIS was found to provide valuable insight into the per-
spective of individuals with FRDA on their health status and
morbidity. However, responsiveness to change appears limited
and its use in intervention studies is questionable.
The ADL part of FARS is another quality-of-life measure,
which is used frequently. As an outcome in the EFACTS study,
it showed effect sizes comparable to those of the SARA.26
Assessment of
Neuropsychological and
Psychiatric Symptoms
Because the cerebellum has a prominent role in motor con-
trol, ataxia patients mainly present with motor symptoms.
The cerebellum plays a role also in nonmotor functions.
Neuropsychological and psychiatric symptoms of variable
severity are encountered in a number of ataxias.27 The rea-
sons for this are 3-fold: (1) Because of cerebellar connections
to nonmotor cortical areas, cerebellar disease can be associated
with neuropsychological symptoms, mainly disturbances of
executive function; (2) in many ataxias, neurodegeneration
extends beyond the sites that result in ataxia by involv-
ing forebrain structures. This results in intellectual impact and
cognitive decline; (3) furthermore, as with many
other chronic brain diseases, ataxia can be associated with
depression.28, 29
There are no instruments that were specifically designed for
assessment of neuropsychological and psychiatric symptoms in
ataxia. Thus, in studies of ataxia patients, various instruments
are used that have been previously developed and validated in
other populations. A comprehensive overview of such studies is
given by Almeida-Silva et al.30
Although neuropsychological and psychiatric abnormalities
have been investigated in numerous studies, there are only a
few multicenter and longitudinal studies.31, 32 A major problem
in the use of timed neuropsychological tests in ataxia patients is
their motor slowness, which is a confounding factor in assessing
cognitive function. This should be taken into account when
selecting specific tests. Neuropsychological tests recommended
in order to minimize motor skills’ interference with special
emphasis on covering executive, visuospatial, and verbal
domains are given in Table 2.
Quantitative Performance Tests
For ataxia, a number of tests are in use that measure perfor-
mance in specific coordinative tasks in a quantitative way.
These tests yield metric, continuous data that facilitate analysis.
In addition, inter-rater reliability is usually higher than in clini-
cal scales. Assessments range from simple time measurements,
for example, the time needed to complete a 25-foot (ft) walk,
syllable repetition rate, and pegboard tests, to complex assess-
ments that require specific equipment, for example, stride
length variability measured with the GAITRite system, acoustic
speech analysis systems,33 and systems to analyse the kinematics
and forces of reaching and grasping movements.34 Each of the
obtained measures reflects only performance in the respective
task. But the results of various tests can be combined to com-
posite measures that are thought to provide a more comprehen-
sive account of disease severity.
Ataxia Functional Composite35
The Ataxia Functional Composite (AFCS) was specifically
designed for FRDA. It is derived from the Multiple Sclerosis
Functional Composite (MSFC) and composed of a timed 25-ft
walk, the 9-hole pegboard test (9HPT), and low-contrast visual
acuity (LCVA). It has been validated in 20 hereditary ataxia
patients, showing a strong correlation to ICARS. Test results
are given as calculated Z scores.
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SCA Functional Index14, 36
The SCA Functional Index (SCAFI) is very similar to the AFCS,
but the LCVA was replaced by a speech test (PATA repetition
rate). The walking test is designated as an 8-m walk, but is essen-
tially identical to the 25-ft walk of the AFCS. The SCAFI score is
derived from the arithmetic mean of the Z scores of the three
tests. The SCAFI reached the criterion for retest reliability and
showed, in general, favorable measurement precision. However,
in longitudinal tests, SCAFI deteriorates within the stable group
of patients during the follow-up period. The clinical relevance of
the longitudinal SCAFI changes seeks further investigation.
Composite Cerebellar Functional Severity
Score37
The Composite Cerebellar Functional Severity Score (CCFS) is
a performance-based scale that combines two tests of upper limb
function, the 9HPT and the click test. Measurements are
adjusted for age and can be used for both for dominant and
recessive ataxias and are adapted for children.38 A version of the
CCFS includes a handwriting test (CCFSw).39, 40 However,
patients with a SARA score of 30 or above may not be able to
perform the CCFS(w).
Posturography41
Posturography is a technique that quantifies postural control in
upright stance in either static or dynamic conditions. It is
widely used for diagnosis of balance disorders. Posturography
using gold-standard laboratory (Codamotion 3D motion analysis
system with Visual 3D offline processing software) has been
used to quantitatively investigate balance (static conditions) in
adults with SCA6. Measures of overall sway speeds as well as
pitch and roll directional components of sway have been used
to comprehensively describe overall and directional components
of instability. Quantitative reports of mean sway speeds correlate
with same-day measures of disease severity (using the SARA),
where an increase in SARA is associated with linear increases in
sway speed. Posturography was additionally used to explore
levels of axial instability. Laboratory investigations of sensory
mechanisms of balance control (dynamic conditions) have
incorporated the use of posturography in order to determine
sensorimotor abnormalities in adults with SCA6.42 Posturogra-
phy requires careful control of sensory conditions to ensure
reliability of highly sensitive measures, but, when achieved, is
feasible as a measure to either track disease progression or to
evaluate the treatment effect of therapies in both clinical and
home settings.43 In addition to standardization of stance width,
foot splay angle, and underfoot surface, standardization of the
visual environment is of considerable importance during testing
given that hypermetric balance responses and increased overall
measures of instability are notable when patients observe mov-
ing scenery in their visual environment.42, 43 Validated portable
measures of posturography (body sway speeds and directional
velocities) include the XSens MTx monitor,43 but posturo-
graphic methods, incorporating other accelerometry-containing
devices, are similarly possible.
TABLE 2 Recommended neuropsychological tests for assessing cognitive functions in ataxia patients*
Domain Function Test Abbreviation References
Global cognitive status General cognitive
functioning
Mini–Mental State Examination MMSE 64
General cognitive
functioning
Montreal Cognitive Assessment MoCA 65
General intellectual
ability
2 Subtests of the Wechsler
Abbreviated Scale of Intelligence:
Vocabulary and Matrix Reasoning
WASI 66
Memory Verbal memory California Verbal Learning Test CVLT 67
Verbal memory Auditory-Verbal Learning Test AVLT 68
Visual memory Continous Visual Memory Test CVMT 69
Executive functions/attention Working memory Digit-Span (Wechsler Adult
Intelligence Scale)
WAIS-IV 70
Interference STROOP Color and Word Test STROOP 71
Verbal fluency
(lexical and semantic)
Controlled Oral Word Association
Test
COWAT 72
Set shifting Wisconsin Card Sorting Test WCST 73
Selective Attention,
Sustained
Attention, Divided
Attention
Test of Everyday Attention TEA 74
Verbal functions and language skills Naming Boston Naming Test BNT 75
Aphasia Bedside Form of the Western
Aphasia Battery-R
WAB-R 76
Reasoning Sequencing Picture Arrangement (Wechsler
Adult Intelligence Scale)
WAIS-R 77
Visuoperceptive Functions Visual recognition Judgment of Line Orientation JLO 78
Depression Severity of depressive
symptoms
Beck Depression Inventory BDI 79
*Considering to minimizing the need for manual response and ataxia as a confounding factor.
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Quantitative Movement Analysis
Computerized gait analyses systems offer an objective and
quantitative measure of gait as well as directed movements. It
has been used in ataxia as an outcome measure in several
nonpharmacological interventional studies. A spatiotemporal
gait analysis system based on infrared diode recording (Vicon)
has been shown to pick-up changes in movement performance
and scores correlate with clinical ataxia scales and with rele-
vance for everyday life.44 GAITRite is a portable, instru-
mented electronics carpet system that allows recording of
stride length and variability during short walking sequences.
GAITRite was validated in study of 25 healthy adults and
showed strong concurrent validity and high test-retest reliabil-
ity.45 In ataxia, it was used in only a few single-center studies.
One study showed that dynamic properties of locomotion in
cerebellar ataxia patients were markedly impaired and that
shifting walking speed away from preferred walking speed
resulted in a loss of dynamic stability.46 The other study
showed that discrete gait abnormalities precede manifest ataxia
in SCA6 mutation carriers compared to manifest SCA6
patients.47 In FRDA, the sensitivity in measuring disease
severity was investigated.48 There are no studies that validate
Vicon or GAITRite as an assessment instrument in multicenter
studies of ataxia patients. However, the feasibility of quantita-
tive gait analysis as an outcome measure for clinical trials in
SCAs has been assessed in a small monocentric study on a
total of 20 SCA1, 2, 3, and 6 patients at two time points, and
data indicated that a high test-retest reliability was demon-
strated. Vicon would also allow quantifying the kinematics of
reaching and grasping movements.
Easy-to-apply hand-held objects that allow measurement of
grip forces, an objective parameter of manual performance,
have been used in single-center trials of patients with mixed
cerebellar pathology.49 They need to be validated in multi-
center studies. The same is true for automatic speech analysis
systems.49
Electrophysiology (Nerve
Conduction Studies, Evoked
Potentials)
Peripheral nerves, dorsal columns, and pyramidal tracts are fre-
quently affected in degenerative ataxias and can be quantita-
tively assessed by neurophysiological tools, such as nerve
conductions studies, somatosensory evoked potentials, and
motor evoked potentials. Neurophysiological tests show charac-
teristic findings in different subtypes of SCA, being present even
in preclinical stages of SCA2.50, 51 In FRDA, nerve conduction
and evoked potential studies demonstrate the sensory neu-
ronopathy, dorsal column degeneration, and pyramidal tract
involvement that characterize the disease. Nerve conduction
studies, by revealing the presence of a peripheral neuropathy
and its type, provide an important support to the differential
diagnosis of recessively inherited ataxias.52 However, multicen-
ter approaches53 and longitudinal studies in ataxias54, 55 are rare
and face major challenges in standardization to assure repro-
ducibility and intercenter comparability of quantitative neuro-
physiological measures, as required for multicenter
interventional trials.
Eye Movement Tracking
Oculomotor disturbances are a common and often early sign in
most hereditary ataxias. Specific oculomotor abnormalities, such
as saccade slowing, are helpful in the diagnosis of hereditary
atxias.56 Presence or absence of oculomotor signs is recorded by
the INAS together with nonataxia signs. Quantitative recording
of eye movements has been performed in several monocentre
studies. However, multicenter and longitudinal approaches face
major challenges in standardization to assure reproducibility and
intercenter comparability. However, given the potential of ocu-
lomotor recording for detection of early or even preclinical
abnomalities, efforts to establish reliable multicenter recording
techniques are strongly encouraged.
Neuroimaging
Neuroimaging allows assessment of the morphological and func-
tional alterations of the brain and spinal cord in ataxia patients.
Most neuroimaging studies in ataxia use MRI, but there are also
molecular imaging studies with radiotracers. A recent consensus
paper discussed application of these neuroimaging methods in
ataxia.57
Magnetic Resonance Imaging (MRI)
Numerous MRI studies have been performed in ataxia patients,
most of which were cross-sectional and done in a single center.
Multicenter longitudinal studies, on the other hand, face
numerous methodological problems, which require rigorous
measures of quality assurance and control. These issues have
been carefully addressed by large consortia investigating patients
with common neurodegenerative diseases, mainly AD, but the
respective standards and recommendations have not yet been
applied to ataxia studies.58
Structural T1-weighted MRI enables quantification of focal
brain atrophy, in particular, of the cerebellum, but also of other
parts of the brain. Images have been analyzed with region of
interest–based volumetry and voxel-based morphometry. A mul-
ticenter study of SCA1, 3, and 6 patients showed brain tissue loss
in the cerebellum and brainstem with a genotype-specific pattern.
In a 2-year longitudinal study of this cohort, the rate of tissue loss
in these structures and basal ganglia nuclei was significantly
greater in patients compared to controls. Some of the volumetric
measures had larger effect sizes than the SARA clinical scale.59
Similarly, there was progressive gray and white matter loss in a
single-center longitudinal study of SCA2 patients.
Diffusion imaging is the method of choice to study white
matter abnormalities, either with diffusion tensor imaging
(DTI) or with more recent mathematical models, for example,
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high-angular resolution diffusion imaging (HARDI), that
describe the 3D displacement distribution of water diffusion.
Although multicenter DTI studies are feasible and there is evi-
dence for white matter involvement in ataxias, DTI has not
yet been assessed in larger ataxia studies. Quantitative MRI
techniques have also potential interest to study tissue proper-
ties, including myelin and iron content with relaxometry and
susceptibility-weighted imaging.60–62 Similarly, functional MRI
in ataxia has been limited to small, single-center, cross-sec-
tional studies. The challenge for multicenter studies lies in the
experimental paradigms used in most functional MRI studies.
MR spectroscopy allows measurement of brain metabolites.63
Its usefulness is limited by the large voxel size in which mea-
surements are made and the difficulty to standardize acquisi-
tions across sites. Again, multicenter studies are lacking. Such
studies will also need to account and correct for different
scanner types.
Molecular Imaging
In molecular imaging, radiotracers are used to assess brain
metabolic activity or label neurotransmitter receptors. Binding
and distribution of the radiotracers in the brain are detected
with PET or single-photon emission computed tomography
(SPECT). PET and SPECT have been used to study glucose
metabolism, dopamine receptors, dopamine transporters, ben-
zodiazepine receptors, and acetylcholine esterase activity in
ataxia patients. Although these studies provided important
insights into the neurobiology of ataxia disorders,63 standard-
ization and validation of the molecular imaging methods as
assessment tools in multicenter ataxia studies is lacking. How-
ever, for AD, a framework for multicenter fluorodeoxyglu-
cose (FDG) PET studies has been defined and applied by the
ADNI consortium.64
Conclusions and
Recommendations
Biomaterials
Given the importance of availability of biomaterials for the
development of biomarkers, biomaterial sampling should take
place in all ataxia patient studies. DNA, RNA, and serum or
plasma and—if possible—PBMC samples should be taken for
analysis of molecular processes and alterations on several molec-
ular levels. Although there are not many publications on molec-
ular properties of CSF samples from ataxia patients, we suggest
CSF sampling for future investigations as well.
To be able to compare biomaterials from different studies, it
is recommended that acquisition, handling, and storage be
performed according to generally accepted standards of
biobanking, as outlined above. This includes documentation of
biomaterial quality. The value of biomaterial samples critically
depends on the availability of standardized clinical data.
Clinical Assessment
Clinical assessment in ataxia studies must include application of
a validated clinical ataxia scale (see Table 1). To facilitate com-
parability between studies, generic ataxia scales, such as SARA
and ICARS, are preferable to scales that are applicable only to
one specific ataxia disease, unless there are particular reasons to
choose a disease-specific scale. In many ataxia disorders, ataxia is
accompanied by additional nonataxia symptoms. Currently,
INAS is the only available instrument to assess these symptoms
comprehensively.
Patient-Reported Measures
Quality of life and the perspective of individuals on their health
status are important outcomes in clinical trials. FAIS or the
ADL part of FARS may be suitable tools.
Assessment of Neuropsychological and
Psychiatric Symptoms
There are no instruments that were specifically designed for
assessment of neuropsychological and psychiatric symptoms in
ataxia. Thus, in studies of ataxia patients, various instruments are
used that have been previously developed and validated in other
populations. A list of tests that may be valuable in monitoring
ataxia patients is given in Table 2. For ataxia, these instruments
need validation in longitudinal and multicenter studies.
Quantitative Performance Tests
Quantitative performance tests have a great potential to serve as
supplementary outcome measures in addition to clinical scales
because they provide objective and quantitative information. It
is therefore hoped that they are more sensitive than clinical
scales. AFCS, SCAFI, and CCFS are each sets of simple timed
tests that do not require expensive equipment or extensive
training. Although they have been sufficiently validated so that
they can be used in multicenter longitudinal studies, there is
currently no evidence that they are more sensitive than clinical
scales. Validated posturographic approaches using gold-standard
laboratory methods or portable home-based devices are feasible
options with the potential to be sensitive continuous outcome
measures for use in multicentered studies. Associated with dis-
ease severity and balance impairment, sway speeds as measures
of instability require careful standardization of sensory condi-
tions to ensure short- and long-term test-retest reliability.
Oculomotor readings have a great potential for detection of
early abnormalities. Efforts to establish reliable multicenter
recording techniques are encouraged.
Neuroimaging
Future multicenter neuroimaging studies in ataxias should
implement quality assurance measures following standards, as
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defined by the ADNI consortium or comparable consortia.
Given that MRI morphometric studies in ataxia yielded robust
results, MRI protocols should include T1-weighted magnetiza-
tion-prepared rapid acquisition gradient echo (MP-RAGE)
sequences that allow morphometric analyses. Because multi-
center studies using other imaging modalities are lacking, no
recommendations concerning specific sequences or protocols
can be given. As an outlook, multimodal integration could be
the way to generate significant makers for follow-up combing
several imaging and clinical tools.
Electrophysiology
Effects on peripheral nerves, dorsal columns, and pyramidal tracts
can be quantitatively assessed by neurophysiological tools, such
as nerve conductions studies, somatosensory evoked potentials,
and motor evoked potentials. Multicenter approaches to longitu-
dinal studies in ataxias are rare and face major challenges in
standardization to assure reproducibility and intercenter compa-
rability.
A brief summary of all conclusions is given in Table 3.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Table S1: SPREC Code Data elements (http://www.isber.
org/?page=SPREC)
Examples of data elements describing the workflow of solid and
fluidic sample processing.
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